Abstract:Introduction: Despite continued improvement in post-sepsis survival, long term morbidity and mortality remain high. Chronic critical illness (CCI), defined as persistent inflammation and organ injury requiring prolonged intensive care, is a harbinger of poor long-term outcomes in sepsis survivors. Current dogma states that sepsis survivors are immunosuppressed, particularly in CCI. Investigation of this immune suppression in heterogeneous immune populations across distinct clinical trajectories and outcomes, along with limited sampling access, is accessible via single-cell RNA sequencing (scRNA-seq). Methods: scRNA-seq analysis was performed on healthy subjects (n=12), acutely septic patients at day 4 ± 1 (n=4), and those defined as rapid recovery (n=4) or CCI (n=5) at day 14-21. Differential gene expression and pathway analyses were performed on peripheral blood lymphocytes at both a population and annotated cell subset level. Cellular function was assessed via enzyme-linked immunosorbent spot (ELISpot), cytokine production analysis, and T-cell proliferation assays on an additional cohort of septic patients (19 healthy, 68 acutely septic, 27 rapid recovery and 20 classified as CCI 14-21 days after sepsis onset). Results: Sepsis survivors that developed CCI exhibited proportional shifts within lymphoid cell populations, with expanded frequency of CD8 + and NK cells. Differential expression and pathway analyses revealed continued activation in T cells and NK cells, with generalized suppression of B-cell function. Both T and NK cell subsets displayed transcriptomic profiles of exhaustion and immunosuppression in CCI, particularly in CD8 + T effector memory (TEM) cells and NK cells. Functional validation of T-cell behavior in an independent cohort demonstrated T cells maintained proliferative responses in vitro yet exhibited a marked loss of cytokine production. IFN-γ production at the acute phase (day 4 ± 1) was significantly reduced in subjects later classified as CCI. Discussion: Sepsis patients exhibit unique T-, B-, and NK-cell transcriptional patterns that are both time- and clinical trajectory-dependent. These transcriptomic and pathway differences in sepsis patients that develop CCI are associated with exhaustion in CD8 + TEM cells and NK cells. Understanding the specific immune system patterns of different cell subsets after sepsis at a molecular level will be key to the development of personalized immunotherapy and drug-targeting intervention. Clinical trial registration: https://clinicaltrials.gov/, identifier NCT02276417.

Resolving sepsis-induced immunoparalysis via trained immunity by targeting interleukin-4 to myeloid cells

Effect of Interleukin-36β on Activating Autophagy of CD4+CD25+ Regulatory T Cells and Its Immune Regulation in Sepsis.

Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis

Time-Dependent Variation in Immunoparalysis Biomarkers Among Patients with Sepsis and Critical Illness

Pathological mechanisms for sepsis-induced immunoparalysis and the therapy

Precision Immunotherapy for Sepsis

Surviving septic patients endotyped with a functional assay demonstrate active immune responses

Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies

The pathophysiology of sepsis and precision-medicine-based immunotherapy

Temporal Changes In Innate And Adaptive Immunity During Sepsis As Determined By Elispot

Unique lymphocyte transcriptomic profiles in septic patients with chronic critical illness

Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes

Adaptive immune function in critical illness

Polymicrobial sepsis influences NK-cell-mediated immunity by diminishing NK-cell-intrinsic receptor-mediated effector responses to viral ligands or infections

Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis

Towards personalized medicine: a scoping review of immunotherapy in sepsis

Β-Glucan-coupled Superparamagnetic Iron Oxide Nanoparticles Induce Trained Immunity to Protect Mice Against Sepsis

Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity

High Mobility Group Protein 1 Reverses Immune System Paralysis in Late-Phase Sepsis

Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response

Adverse outcomes and an immunosuppressed endotype in septic patients with reduced IFN-γ ELISpot